Neurocrine Biosciences (NBIX) Short term Debt (2018 - 2024)

Neurocrine Biosciences has reported Short term Debt for 6 years, with the latest figure at $122.8 million in Q1 2024.

• For the quarter ending Q1 2024, Short term Debt changed N/A year-over-year to $122.8 million; the trailing twelve-month figure through Mar 2024 stood at $122.8 million (changed N/A YoY), and the FY2023 full-year result was $170.1 million, changed 0.41% from the prior year.
• Short term Debt for Q1 2024 stood at $122.8 million, down from $170.1 million in the prior quarter.
• The five-year high for Short term Debt was $425.0 million in Q3 2020, with the low at $122.8 million in Q1 2024.
• Historically, Short term Debt has averaged $227.0 million across 4 years, with a median of $169.8 million in 2023.
• The largest YoY upside for Short term Debt was 0.41% in 2023 against a maximum downside of 0.41% in 2023.
• Neurocrine Biosciences' Short term Debt stood at $425.0 million in 2020, then sank by 60.14% to $169.4 million in 2022, then rose by 0.41% to $170.1 million in 2023, then declined by 27.81% to $122.8 million in 2024.
• The last three Short term Debt figures came in at $122.8 million (Q1 2024), $170.1 million (Q4 2023), and $169.9 million (Q3 2023), per Business Quant data.